Arcturus Enters Reverse-Merger With Alcobra To Push Differentiated RNA Approach

One company’s disappointment is another’s opportunity, as Arcturus will go public by merging with troubled Alcobra. The combined company will have seven preclinical programs, four run by partners.

Handshake of businessmen

Arcturus Therapeutics Inc. will get a public structure and added cash to make good on its ambitions to improve on other RNA therapeutics companies’ offerings as it enters a reverse-merger with troubled Israeli biotech Alcobra Ltd.

The all-stock transaction announced on Sept. 28, which has been approved by both companies’ boards of directors but still needs shareholder approval, would give Arcturus a 60% interest in the combined firm; Alcobra shareholders hold onto 40% largely thanks to the $35m in cash it will bring to the merger. Under the new name Arcturus Therapeutics Ltd

More from Deals

More from Business